Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 6/20 | 0.57 |
| ▸ | KCNK9 | Q9NPC2 | 6/20 | 0.57 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23143565 | 0.92 | TRPV1 (0.56) | CRBNTRPV1SMYD3 | |
| SCHEMBL395950 | 0.90 | TRPV1 (0.59) | KCNK3KCNK9CRBNTRPV1TP53 | |
| SCHEMBL3660176 | 0.82 | SMYD3 (0.58) | TRPV1SMYD3 | |
| SCHEMBL31139504 | 0.82 | SMYD3 (0.58) | TRPV1SMYD3 | |
| SCHEMBL5842454 | 0.82 | TLK2 (0.57) | KCNK3KCNK9TP53SMYD3 | |
| SCHEMBL24124323 | 0.82 | TRPV1 (0.50) | CRBNTRPV1SIRT1SMYD3 | |
| SCHEMBL25921128 | 0.81 | GPR27 (0.60) | TRPV1KMT2AMEN1POLBMAPT | |
| SCHEMBL3581648 | 0.80 | KCNK3 (0.54) | KCNK3KCNK9CRBNKMT2AMEN1 | |
| SCHEMBL29899567 | 0.80 | BACE1 (0.56) | CRBNTRPV1KMT2AMEN1TP53 | |
| SCHEMBL23143516 | 0.80 | BACE1 (0.56) | CRBNTRPV1KMT2AMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101608-B2 | 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC, a Delware Limited Corporation (BM) | 2012-01-24 | — | — | US | disclosed |